MRC Technology Announces Humanization of Anti-Tau Monoclonal Antibody for Alzheimers Disease Therapy
MRC Technology has successfully humanized an anti-tau monoclonal antibody, which has applications in the treatment of Alzheimer’s and related neurodegenerative tauopathies. The humanized tau antibody represents an important milestone for developing a disease modifying immunotherapy for Alzheimer’s disease. MRC Technology was contracted to humanize the antibody by AXON Neuroscience SE, a biotechnology company dedicated to the development of disease modifying immunotherapeutics and early diagnostics for Alzheimer's disease.
Alzheimer’s disease is characterized by the presence of neurofibrillary tangles consisting of diseased forms of protein tau. Tau cortical neurofibrillary tangles correlate well with the severity of cognitive impairment in Alzheimer’s disease and thus represent a valuable target for disease modifying therapy. Targeting disease modified tau appears to be a promising way to slow down or even stop progression of the disease.
Michael Dalrymple, Director of Business Development at MRC Technology, said: "We are very pleased with the outcome of this project and are hopeful that the positive evaluation results for the humanized antibody will prove to be a milestone in the development of effective treatments for this debilitating disease.”
“Treatment of Alzheimer’s disease is still recognised as an unmet medical need. Our company has considerable expertise in the area and I believe we are on the right track to developing an effective therapy that has the potential to stop progress of the disease,” commented Roman Sivak, Chief Executive Officer at AXON Neuroscience. “We thank MRC Technology for their invaluable support in humanizing this antibody, an essential step in its development as an immune-based therapeutic.”
Related News
-
News Moderna to buy OriCiro Genomics in USD $85 million deal
Pharmaceutical company Moderna acquires genomics services company OriCiro Genomics, based in Tokyo, Japan, to boost mRNA therapeutics development and manufacturing portfolio. -
News New year, new prices: at least 350 drugs in USA to see price increases in January
Drugmakers such as Pfizer, GSK, BMS, AstraZeneca, and Sanofi are planning to raise prices for at least 350 unique drugs in the United States in early January. -
Sponsored Content 2023 Pharma Trend Outlook: Innovation, Resilience, and Pharma 4.0
Download our 2023 Pharma Trends Outlook report to discover the trends set to shape the pharmaceutical landscape in the new year, with expert opinions and insight from across the pharmaceutical value chain. -
News Strategic partnership between AstraZeneca and G42 Healthcare to increase pharmaceutical manufacturing in Abu Dhabi
A comprehensive, long-term partnership agreement between AstraZeneca and G42 Healthcare is set to enhance local drug manufacturing in Abu Dhabi, UAE, and bolster pharmaceutical manufacturing innovation within the country. -
News CordenPharma joins sustainability initiative to achieve Net Zero
The CDMO has joined the environmental initiative looking to align private sector companies with those aims upheld by the Paris Agreement to reduce global warming. -
News AstraZeneca acquires Neogene in shift into cell-based cancer therapies
AstraZeneca has recently announced that it will be acquiring the biotechnology company Neogene Therapeutics as part of it’s expansion into cell-based cancer treatments.
-
News A mRNA universal flu vaccine is in early stages of development
Researchers from the University of Pennsylvania have developed a universal flu vaccine using nanoparticle encapsulated mRNA. -
News Biovac partnership to increase African vaccine manufacturing capabilities
South African biopharma company Biovac signs a partnership deal with the International Vaccine Institute to develop and manufacture an oral cholera vaccine for both the African and global market.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance